<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Treatment and prevention of Pneumocystis infection in patients with HIV
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Treatment and prevention of Pneumocystis infection in patients with HIV
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Treatment and prevention of Pneumocystis infection in patients with HIV
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul E Sax, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rajesh T Gandhi, MD, FIDSA
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Milana Bogorodskaya, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 12, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          Pneumocystis jirovecii
         </em>
         pneumonia (formerly called
         <em>
          Pneumocystis carinii
         </em>
         pneumonia or PCP) is the most common opportunistic respiratory infection in patients with acquired immunodeficiency syndrome (AIDS). It typically occurs in patients with human immunodeficiency virus (HIV) with a CD4 count &lt;200 cells/microL who are not receiving antiretroviral therapy or appropriate prophylaxis.
        </p>
        <p>
         This topic will review the treatment and prevention of PCP in patients with HIV infection. Topic reviews on the clinical presentation and diagnosis of PCP in patients with HIV and PCP in the HIV-uninfected host are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3704.html" rel="external">
          "Epidemiology, clinical presentation, and diagnosis of Pneumocystis pulmonary infection in patients with HIV"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1406.html" rel="external">
          "Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in patients without HIV"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1393.html" rel="external">
          "Treatment and prevention of Pneumocystis pneumonia in patients without HIV"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H23513275">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antimicrobial therapy directed against
         <em>
          P. jirovecii
         </em>
         is the mainstay of treatment for
         <em>
          Pneumocystis
         </em>
         pneumonia (PCP). In addition, some patients will require adjunctive corticosteroids. Antiretroviral therapy (ART) should be initiated to restore immune function. Although PCP is uncommon in those on ART, for those patients already receiving it, we continue their ART regimen while they are being treated for PCP. (See
         <a class="medical medical_review" href="/z/d/html/3773.html" rel="external">
          "Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach"
         </a>
         and
         <a class="local">
          'Timing of ART initiation'
         </a>
         below.)
        </p>
        <p>
         Empiric therapy for PCP should be initiated pending the results of the diagnostic evaluation if there is a high clinical suspicion for PCP (eg, CD4 count &lt;200 cells/microL, hypoxemia, interstitial infiltrates). In certain situations, it is not possible to confirm the diagnosis, and patients are treated and monitored for clinical response (see
         <a class="local">
          'Monitoring patients on treatment'
         </a>
         below). A detailed discussion on the clinical manifestations and diagnosis of PCP is found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3704.html" rel="external">
          "Epidemiology, clinical presentation, and diagnosis of Pneumocystis pulmonary infection in patients with HIV"
         </a>
         .)
        </p>
        <p>
         After patients complete their initial treatment regimen, antimicrobial therapy should be continued at lower doses to prevent recurrent infection (ie, secondary prophylaxis). This preventive therapy can be discontinued after immune recovery has been achieved for a prolonged period of time. (See
         <a class="local">
          'Secondary prophylaxis'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H23512798">
         <span class="h2">
          Initial assessment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several factors impact the approach to treatment for patients with PCP. Thus, prior to initiating therapy, we assess the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Drug allergies
         </strong>
         –
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          Trimethoprim-sulfamethoxazole
         </a>
         (TMP-SMX), a sulfa-containing regimen, is the preferred treatment for PCP. For patients with a sulfa allergy, a second-line regimen is generally used. However, we may desensitize certain patients to TMP-SMX, such as those with severe PCP, if their sulfa allergy is non-life threatening. (See
         <a class="local">
          'Preferred regimen'
         </a>
         below and
         <a class="local">
          'Alternative regimens'
         </a>
         below and
         <a class="local">
          'Desensitization for patients with a sulfa allergy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Respiratory status
         </strong>
         – We evaluate the patient’s respiratory status to help assess the severity of disease. We first assess the patient clinically by measuring their respiratory rate and evaluating the use of accessory muscles of respiration. We then measure arterial oxygenation using pulse oximetry. (See
         <a class="medical medical_review" href="/z/d/html/3721.html" rel="external">
          "Evaluation of pulmonary symptoms in persons with HIV", section on 'Pulse oximetry or arterial blood gas analysis'
         </a>
         .)
         <strong>
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In patients with evidence of respiratory distress, tachypnea, and/or hypoxia, the severity of disease can be further assessed by obtaining a blood gas (eg, alveolar to arterial oxygen [A-a] gradient). However, with the reliability of pulse oximetry, we no longer obtain a blood gas solely to determine the need for corticosteroids if a patient has clear evidence of hypoxemia (eg, resting room air oxygen saturation &lt;92 percent). A blood gas may still be useful to help determine if the patient requires placement in the intensive care unit and/or if an intravenous regimen should be used. (See
         <a class="local">
          'Severe disease'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Factors that impact absorption
         </strong>
         – Most patients with PCP can be treated with an oral regimen. However, some individuals may have a concurrent condition that impacts their ability to take an oral medication (eg, severe esophageal candidiasis, diarrhea). Such patients will require intravenous (IV) therapy until these other conditions have improved.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H494481457">
         <span class="h2">
          Approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         The initial approach to treatment (eg, the choice of agent, the mode of administration, and the use of adjunctive corticosteroids) is determined primarily by the level of oxygenation and/or the A-a gradient. An overview of the management of patients with mild, moderate, or severe disease is reviewed here. A discussion of the specific antimicrobial agents is found below. (See
         <a class="local">
          'Antimicrobial regimens'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H549879690">
         <span class="h3">
          Mild disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with mild disease have an A-a O
         <sub>
          2
         </sub>
         gradient &lt;35 mmHg and/or a partial pressure of arterial oxygen ≥70 mmHg.
        </p>
        <p>
         We administer oral therapy to such patients unless they have a concurrent infection or comorbidity that would impact drug absorption. We suggest TMP-SMX for treatment of mild disease; alternative regimens include trimethoprim-dapsone, clindamycin-primaquine, or
         <a class="drug drug_general" data-topicid="8957" href="/z/d/drug information/8957.html" rel="external">
          atovaquone
         </a>
         . Such patients do
         <strong>
          not
         </strong>
         require corticosteroids. (See
         <a class="local">
          'Preferred regimen'
         </a>
         below and
         <a class="local">
          'Alternative regimens for mild to moderate disease'
         </a>
         below and
         <a class="local">
          'Whom to treat with corticosteroids'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H402141829">
         <span class="h3">
          Moderate disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with moderate disease have an A-a O
         <sub>
          2
         </sub>
         gradient ≥35 and &lt;45 mmHg and/or a partial pressure of arterial oxygen ≥60 and &lt;70 mmHg.
        </p>
        <p>
         As with mild disease, we administer oral therapy unless the patient has a concurrent infection or comorbidity that would impact absorption. We suggest TMP-SMX for treatment of moderate disease. Alternative regimens include trimethoprim-dapsone or clindamycin-primaquine; we generally do not use
         <a class="drug drug_general" data-topicid="8957" href="/z/d/drug information/8957.html" rel="external">
          atovaquone
         </a>
         as initial treatment for moderate disease. In addition, individuals with moderate disease require adjunctive corticosteroids. (See
         <a class="local">
          'Preferred regimen'
         </a>
         below and
         <a class="local">
          'Alternative regimens for mild to moderate disease'
         </a>
         below and
         <a class="local">
          'Corticosteroid regimen'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H549879554">
         <span class="h3">
          Severe disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         A patient has severe disease when the A-a O
         <sub>
          2
         </sub>
         gradient is ≥45 mmHg, the partial pressure of arterial oxygen is &lt;60 mmHg, and/or there is potential for fatigue leading to respiratory failure (eg, a high respiratory rate or a partial pressure of arterial carbon dioxide that is normal or higher than normal in a patient with hypoxia).
        </p>
        <p>
         We recommend TMP-SMX for patients with severe disease. Individuals should receive intravenous therapy until they are clinically stable (eg, PaO2 ≥60 mmHg, respiratory rate &lt;25) and are able to be transitioned to oral treatment. Adjunctive corticosteroids should also be administered. (See
         <a class="local">
          'Preferred regimen'
         </a>
         below and
         <a class="local">
          'Corticosteroid regimen'
         </a>
         below.)
        </p>
        <p>
         For those with severe disease who cannot take TMP-SMX (eg, severe sulfonamide allergy), we typically suggest clindamycin-primaquine. For such patients, we obtain a detailed history to assess the type and severity of their past sulfonamide reaction since certain individuals can be desensitized to TMP-SMX. (See
         <a class="local">
          'Alternative regimens for severe disease'
         </a>
         below and
         <a class="local">
          'Desensitization for patients with a sulfa allergy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1154921003">
         <span class="h3">
          Indications for hospitalization
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with PCP sometimes worsen after two to three days of therapy. This must be taken into consideration when deciding who requires hospitalization. In general, the following are indications for inpatient therapy: disease severe enough to warrant treatment with corticosteroids, regardless of whether intravenous or oral anti-Pneumocystis therapy is used; initial treatment with intravenous
         <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">
          pentamidine
         </a>
         given the potential side effects of therapy (in particular, hypoglycemia and hypotension); and patients for whom compliance with therapy or laboratory monitoring is likely to be difficult.
        </p>
        <p class="headingAnchor" id="H494481841">
         <span class="h2">
          Antimicrobial regimens
         </span>
        </p>
        <p class="headingAnchor" id="H887412817">
         <span class="h3">
          Preferred regimen
         </span>
         <span class="headingEndMark">
          —
         </span>
         TMP-SMX is the preferred regimen for the treatment of PCP in patients with HIV  (
         <a class="graphic graphic_table graphicRef61052" href="/z/d/graphic/61052.html" rel="external">
          table 1
         </a>
         ). Therapy should be administered for 21 days.
         <a class="drug drug_general" data-topicid="10024" href="/z/d/drug information/10024.html" rel="external">
          Trimethoprim
         </a>
         is a dihydrofolate reductase inhibitor, and sulfamethoxazole is a dihydropteroate synthetase inhibitor; when coupled together they are synergistic in eradicating
         <em>
          P. jirovecii
         </em>
         . (See
         <a class="medical medical_review" href="/z/d/html/493.html" rel="external">
          "Trimethoprim-sulfamethoxazole: An overview"
         </a>
         .)
        </p>
        <p>
         The standard dose of TMP-SMX is 15 to 20 mg/kg/day orally or intravenously in three or four divided doses. Dosing of TMP-SMX is based upon the TMP component and expressed as mg/kg per day of TMP. In certain circumstances, such as in patients with comorbidities, lower doses of TMP-SMX can be considered. Dose modifications for renal impairment may be needed; detailed dosing recommendations are available in the TMP-SMX drug information monograph included within UpToDate.
        </p>
        <p>
         The severity of disease dictates whether oral or intravenous therapy should be used:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with mild to moderate disease, we prefer oral therapy since TMP-SMX has excellent oral absorption. For most patients, this turns out to be two double-strength tablets given every six or eight hours, depending upon body weight.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with severe disease, we administer IV therapy. (See
         <a class="local">
          'Severe disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
         We treat with TMP-SMX even if the patient was prescribed TMP-SMX for PCP prophylaxis (see
         <a class="local">
          'Preventing initial infection'
         </a>
         below). Most patients who develop PCP while being prescribed TMP-SMX prophylaxis do so because of non-adherence to their medication [
         <a href="#rid1">
          1
         </a>
         ]. Although sulfa-containing agents can result in resistance mutations in the dihydropteroate synthase gene of
         <em>
          P. jirovecii
         </em>
         [
         <a href="#rid2">
          2
         </a>
         ], drug resistance leading to treatment failure is unlikely [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         The efficacy of TMP-SMX for treating PCP has been most clearly demonstrated in individuals with severe disease [
         <a href="#rid4">
          4-8
         </a>
         ]. As an example, in a randomized trial of 70 patients with severe PCP that compared TMP-SMX with
         <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">
          pentamidine
         </a>
         , the survival rate was significantly higher in those receiving TMP-SMX (86 versus 61 percent) [
         <a href="#rid5">
          5
         </a>
         ]. Among those with mild to moderate disease, there are no high quality data to support the use of TMP-SMX over one of the other agents. However, based upon our clinical experience, and the experience of other experts [
         <a href="#rid9">
          9
         </a>
         ], we suggest TMP-SMX for initial treatment of mild to moderate PCP. (See
         <a class="local">
          'Alternative regimens for mild to moderate disease'
         </a>
         below.)
        </p>
        <p>
         There are accumulating data that lower doses of TMP-SMX are just as effective as standard-dose TMP-SMX at treating PCP. In a meta-analysis of three studies in patients with HIV, lower doses of TMP-SMX (10 to 12 mg/kg/day) were associated with similar three-month mortality rate compared with a historical standard-dose TMP-SMX cohort (9 versus 11 percent) [
         <a href="#rid10">
          10
         </a>
         ]. A randomized, controlled trial comparing low- and standard-dose of TMP-SMX is ongoing [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H23513281">
         <span class="h3">
          Alternative regimens
         </span>
         <span class="headingEndMark">
          —
         </span>
         For those who are unable to take TMP-SMX, the choice of which alternative agent to use is based upon the severity of disease, the patient’s intolerances and allergies, and the ease of administration  (
         <a class="graphic graphic_table graphicRef61052" href="/z/d/graphic/61052.html" rel="external">
          table 1
         </a>
         ). Dose modifications for renal impairment may be needed for certain agents; detailed dosing recommendations are available in the specific drug information monographs included within UpToDate.
        </p>
        <p class="headingAnchor" id="H461789961">
         <span class="h4">
          Alternative regimens for mild to moderate disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several alternative regimens can be used for the treatment of mild to moderate disease; the available data do not favor one over the other. This was illustrated in a multicenter trial that randomly assigned 181 patients with mild to moderate PCP (defined as an A-a O
         <sub>
          2
         </sub>
         gradient &lt;45 mmHg) to therapy with TMP-SMX, TMP-dapsone, or clindamycin-primaquine for 21 days [
         <a href="#rid1">
          1
         </a>
         ]. Patients with an A-a O
         <sub>
          2
         </sub>
         gradient between 35 and 45 mmHg also received corticosteroids. There was no significant difference between groups in the rate of treatment failure or mortality (approximately 5 percent in each treatment arm). However, the risk of hematologic and hepatotoxicity were significantly more frequent in those receiving clindamycin-primaquine and TMP-SMX, respectively.
        </p>
        <p>
         The following oral regimens should be administered for 21 days, and are listed in order of our preference:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Trimethoprim-dapsone
         </strong>
         – Oral
         <a class="drug drug_general" data-topicid="10024" href="/z/d/drug information/10024.html" rel="external">
          trimethoprim
         </a>
         is administered at a dose of 5 mg/kg (typically rounded to the nearest 100 milligrams) three times per day with
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          dapsone
         </a>
         100 mg per day. Dapsone is a sulfone that is usually tolerated by persons who have adverse reactions to TMP-SMX [
         <a href="#rid12">
          12,13
         </a>
         ]. However, in patients who have had serious reactions to TMP-SMX (eg, Stevens Johnson syndrome/toxic epidermal necrolysis, rash with fever and systemic symptoms, serum sickness, or hemolytic anemia), it seems prudent to avoid dapsone. (See
         <a class="medical medical_review" href="/z/d/html/2080.html" rel="external">
          "Sulfonamide allergy in HIV-uninfected patients", section on 'Cross-reactivity'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clindamycin-primaquine
         </strong>
         – Oral clindamycin-primaquine is administered as
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         (450 mg every six hours or 600 mg every eight hours) along with
         <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">
          primaquine
         </a>
         base 30 mg per day.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8957" href="/z/d/drug information/8957.html" rel="external">
          Atovaquone
         </a>
         – Atovaquone suspension can be used for the treatment of mild PCP (see
         <a class="local">
          'Mild disease'
         </a>
         above). The dose is 750 mg twice daily and should be taken with food [
         <a href="#rid14">
          14
         </a>
         ]. In general, we do not use this agent for the initial treatment of moderate disease since atovaquone was less effective than TMP/SMX in a comparative clinical trial [
         <a href="#rid15">
          15
         </a>
         ]. However, we may switch a patient with moderate to severe disease to atovaquone if they are clinically improved on a more potent agent, but have developed an adverse reaction.
        </p>
        <p>
        </p>
        <p>
         Patients should be tested for glucose-6-phosphate dehydrogenase (G6PD) deficiency when using a regimen that contains
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          dapsone
         </a>
         or
         <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">
          primaquine
         </a>
         since patients with G6PD deficiency are at risk for developing hemolytic anemia when exposed to these agents. Sulfa-intolerant patients with G6PD deficiency and mild disease should receive
         <a class="drug drug_general" data-topicid="8957" href="/z/d/drug information/8957.html" rel="external">
          atovaquone
         </a>
         . For those with G6PD deficiency and moderate disease, the decision to use atovaquone, desensitize to TMP-SMX, or switch to IV therapy with
         <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">
          pentamidine
         </a>
         depends upon the severity of their disease and their past reaction to TMP-SMX. Although it is best if G6PD results are available prior to initiating treatment, therapy may be initiated simultaneously with testing as the risk for this deficiency is quite low. (See
         <a class="medical medical_review" href="/z/d/html/3741.html" rel="external">
          "Initial evaluation of adults with HIV", section on 'G6PD deficiency'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7111.html" rel="external">
          "Diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H461789977">
         <span class="h4">
          Alternative regimens for severe disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest clindamycin-primaquine for patients with severe disease who cannot take TMP-SMX. However,
         <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">
          primaquine
         </a>
         must be administered orally; thus, IV
         <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">
          pentamidine
         </a>
         must be used for patients with severe PCP who have a life-threatening sulfonamide allergy and cannot take oral medications. Such patients should be switched to a less toxic regimen as soon as they can tolerate oral therapy.
        </p>
        <p>
         We prefer clindamycin-primaquine rather than IV
         <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">
          pentamidine
         </a>
         based upon the lower rate of severe side effects. In addition, although there are no randomized clinical trials comparing clindamycin-primaquine with pentamidine for treatment of severe PCP, the former appears to be more effective and better tolerated than pentamidine when used as second-line therapy in patients who cannot take or fail TMP-SMX [
         <a href="#rid8">
          8,16,17
         </a>
         ]. (See
         <a class="local">
          'Treatment failure'
         </a>
         below.)
        </p>
        <p>
         Specific information regarding the alternative regimens includes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clindamycin-primaquine
         </strong>
         –
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          Clindamycin
         </a>
         can be administered intravenously at a dose of 600 mg every six hours or 900 mg every eight hours. Patients should receive intravenous therapy until they are clinically stable (eg, PaO2 ≥60 mmHg, respiratory rate &lt;25) and have a functioning gastrointestinal tract; after that, they can transition to oral clindamycin (450 mg every six hours or 600 mg every eight hours).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">
          Primaquine
         </a>
         base is given orally at a dose of 30 mg daily. Patients should be tested for G6PD when initiating this regimen since patients with G6PD deficiency are at risk for developing hemolytic anemia when exposed to primaquine. (See
         <a class="medical medical_review" href="/z/d/html/3741.html" rel="external">
          "Initial evaluation of adults with HIV", section on 'G6PD deficiency'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7111.html" rel="external">
          "Diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency", section on 'Acute hemolytic anemia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">
          Pentamidine
         </a>
         – Pentamidine is administered intravenously at a dose of 4 mg/kg daily. We avoid pentamidine in patients with renal insufficiency (estimated glomerular filtration rate &lt;60 mL/min/1.73m
         <sup>
          2
         </sup>
         ), as well as those with concurrent pancreatitis because of its potential toxicities. (See
         <a class="local">
          'Adverse reactions'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients who require treatment with
         <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">
          pentamidine
         </a>
         should be admitted to the hospital and closely monitored with bedside telemetry and frequent measurement of blood pressure. The drug should be administered over at least 60 minutes while the patient is supine and adequately hydrated.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Adverse reactions to
         <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">
          pentamidine
         </a>
         are common and can be severe. Individuals who improve while on pentamidine should be switched to a safer oral regimen as soon as clinically feasible. However, the pentamidine dose can be reduced to 3 mg/kg IV daily for patients who experience toxicity if no other treatment option is possible. (See
         <a class="local">
          'Adverse reactions'
         </a>
         below and
         <a class="local">
          'Alternative regimens for mild to moderate disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
         Although there are some reports of echinocandin use in patients intolerant to or failing TMP-SMX therapy, further study is needed to delineate their role in PCP treatment [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
         For patients with a sulfa allergy, we obtain a detailed history to assess the type and severity of their past reaction; this will allow us to determine if it is safe for them to be desensitized to TMP-SMX. Patients who undergo desensitization should continue treatment with one of these alternative regimens until they are able to tolerate treatment doses of TMP-SMX. (See
         <a class="local">
          'Desensitization for patients with a sulfa allergy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H23512922">
         <span class="h2">
          Use of corticosteroids
         </span>
         <span class="headingEndMark">
          —
         </span>
         Corticosteroids given in conjunction with anti-Pneumocystis therapy can decrease the incidence of mortality and respiratory failure associated with PCP [
         <a href="#rid19">
          19
         </a>
         ]. Without steroids, patients with PCP may worsen clinically after two to three days of therapy, presumably due to increased inflammation in response to dying organisms. (See
         <a class="medical medical_review" href="/z/d/html/3704.html" rel="external">
          "Epidemiology, clinical presentation, and diagnosis of Pneumocystis pulmonary infection in patients with HIV", section on 'Clinical Features of Pulmonary disease'
         </a>
         .)
        </p>
        <p>
         Several randomized trials have demonstrated the benefits of administering corticosteroids to patients with PCP who have abnormalities in oxygen exchange at the time of presentation [
         <a href="#rid20">
          20-22
         </a>
         ]. These findings were illustrated in a Cochrane Database review of seven randomized controlled trials that evaluated the effects of adjunctive corticosteroids in patients with HIV with moderate to severe disease [
         <a href="#rid19">
          19
         </a>
         ]. Compared with placebo, the risk ratios for overall mortality in patients receiving adjunctive corticosteroids were 0.56 (95% CI 0.32-0.98) at one month and 0.59 (95% CI 0.41-0.85) at three to four months of follow-up.
        </p>
        <p class="headingAnchor" id="H23512971">
         <span class="h3">
          Whom to treat with corticosteroids
         </span>
         <span class="headingEndMark">
          —
         </span>
         We recommend the use of adjunctive corticosteroids for patients with moderate to severe disease  (
         <a class="graphic graphic_table graphicRef61052" href="/z/d/graphic/61052.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Moderate disease'
         </a>
         above and
         <a class="local">
          'Severe disease'
         </a>
         above.)
        </p>
        <p>
         If blood gas data are available, we agree with guideline panels and initiate steroids in patients with [
         <a href="#rid9">
          9,23
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A partial pressure of oxygen of &lt;70 mmHg on room air
         <strong>
          and/or
         </strong>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An alveolar-arterial (A-a) oxygen gradient of ≥35 mmHg
        </p>
        <p>
        </p>
        <p>
         However, with the reliability of pulse oximetry, we no longer obtain a blood gas solely to determine the need for corticosteroids if a patient has clear evidence of hypoxemia (eg, resting room air oxygen saturation &lt;92 percent). A blood gas may still be useful to help determine if the patient requires placement in the intensive care unit and/or if an intravenous regimen should be used. (See
         <a class="local">
          'Severe disease'
         </a>
         above.)
        </p>
        <p>
         We also administer corticosteroids to patients with worsening respiratory symptoms after starting treatment. Although there are no controlled studies evaluating the use of corticosteroids in this setting, one case series suggested there may be some benefit [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H23512991">
         <span class="h3">
          Corticosteroid regimen
         </span>
         <span class="headingEndMark">
          —
         </span>
         Corticosteroids should be initiated
         <strong>
          concurrently
         </strong>
         with anti-
         <em>
          Pneumocystis
         </em>
         therapy. Although studies have not demonstrated the optimal dose or duration of therapy, we administer the following 21-day oral regimen [
         <a href="#rid9">
          9,23
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          Prednisone
         </a>
         40 mg twice daily for 5 days
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         followed by
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          Prednisone
         </a>
         40 mg daily for 5 days
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         followed by
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          Prednisone
         </a>
         20 mg daily for 11 days
        </p>
        <p>
        </p>
        <p>
         Intravenous
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         can be substituted for oral
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         at 75 percent of the prednisone dose if IV therapy is necessary.
        </p>
        <p class="headingAnchor" id="H1055246759">
         <span class="h2">
          Pregnancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         TMP-SMX is the preferred therapy for PCP in pregnant women. If an alternative regimen must be used, we prefer trimethoprim-dapsone since there is clinical experience with this regimen in pregnancy [
         <a href="#rid9">
          9
         </a>
         ]. (See
         <a class="local">
          'Preferred regimen'
         </a>
         above and
         <a class="local">
          'Alternative regimens for mild to moderate disease'
         </a>
         above.)
        </p>
        <p>
         However, there are risks associated with the use of TMP-SMX and
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          dapsone
         </a>
         in pregnancy. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         First-trimester exposure to TMP-SMX has been associated with an increased risk for neural tube defects and cardiovascular, urinary tract, and other anomalies [
         <a href="#rid25">
          25
         </a>
         ].
         <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">
          Folic acid
         </a>
         supplementation may reduce this risk [
         <a href="#rid26">
          26
         </a>
         ], but there are concerns that folic acid can lead to increased treatment failures in patients being treated for PCP. Thus, we administer folic acid only to women in the first trimester. In addition, we obtain a follow-up ultrasound at 18 to 20 weeks to assess fetal anatomy [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If sulfa drugs or
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          dapsone
         </a>
         are used near delivery, neonatal providers should be informed since there is an increased risk of kernicterus.
        </p>
        <p>
        </p>
        <p>
         We do
         <strong>
          not
         </strong>
         use intravenous
         <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">
          pentamidine
         </a>
         in pregnant women since animal studies suggest that pentamidine can cause embryonic toxicity and death when administered at doses similar to those used in humans [
         <a href="#rid27">
          27
         </a>
         ]. (See
         <a class="local">
          'Alternative regimens for severe disease'
         </a>
         above.)
        </p>
        <p>
         The indications for corticosteroids are the same as in nonpregnant patients; however, pregnant women should be followed closely for gestational diabetes when treated with corticosteroids during the third trimester. Some women may also require stress dose corticosteroids during delivery [
         <a href="#rid9">
          9
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/146.html" rel="external">
          "The management of the surgical patient taking glucocorticoids"
         </a>
         .)
        </p>
        <p>
         More detailed discussions on the use of TMP-SMX in pregnancy are found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/493.html" rel="external">
          "Trimethoprim-sulfamethoxazole: An overview", section on 'Pregnancy and breastfeeding'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13972.html" rel="external">
          "Prenatal evaluation of women with HIV in resource-rich settings", section on 'Chemoprophylaxis for opportunistic infections'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H536523312">
         <span class="h2">
          Prognosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients being treated for PCP will improve on therapy. However, some patients develop progressive respiratory failure, even with appropriate treatment. Studies done prior to the widespread use of antiretroviral therapy found that response to treatment depends, in part, upon the degree of hypoxia at presentation [
         <a href="#rid1">
          1,22,28,29
         </a>
         ]. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with mild to moderate disease (A-a O
         <sub>
          2
         </sub>
         gradient ≤45 mmHg) had a case fatality rate &lt;10 percent [
         <a href="#rid1">
          1
         </a>
         ], whereas patients with more severe abnormalities in gas exchange had a case fatality &gt;20 percent [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The mortality among patients with PCP and respiratory failure requiring intensive care admission or mechanical ventilation was reported to be as high as 60 percent [
         <a href="#rid30">
          30-33
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Other factors that correlate with poor outcome include increasing age, a prior episode of PCP, an elevated serum lactate dehydrogenase concentration, a low CD4 cell count, and the presence of cytomegalovirus in bronchoalveolar lavage fluid [
         <a href="#rid28">
          28,29,34-36
         </a>
         ].
        </p>
        <p>
         Initiating antiretroviral therapy (ART) improves the prognosis of patients with PCP and advanced HIV-related immunosuppression [
         <a href="#rid36">
          36-38
         </a>
         ]. In an observational study that included 5222 episodes of PCP occurring among 4412 patients, the 12-month survival increased from 40 percent in 1992 to 1993 to 63 percent in 1996 to 1998 (ie, after the introduction of potent ART) [
         <a href="#rid36">
          36
         </a>
         ]. Administering antiretroviral therapy soon after treatment for PCP is initiated provides the best benefit. (See
         <a class="local">
          'Timing of ART initiation'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H23513314">
         <span class="h2">
          Monitoring patients on treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients should be monitored for adverse events related to their treatment regimen, as well as their response to therapy.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with mild to moderate disease being treated as an outpatient, we schedule a follow-up visit within one week of starting treatment to perform a clinical assessment and obtain laboratory testing. At that visit, we measure the oxygen saturation, obtain a complete blood count, and measure renal function, electrolytes, and aminotransferase levels.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with severe disease requiring hospitalization, daily clinical assessments and more frequent laboratory monitoring are needed. For such patients, we monitor complete blood counts, electrolytes, and liver function tests at least two to three times per week. Individuals receiving
         <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">
          pentamidine
         </a>
         should have renal function, glucose, calcium, and electrolyte concentrations monitored daily; such patients should be switched to a less toxic regimen as soon as they can tolerate oral therapy. (See
         <a class="local">
          'Alternative regimens'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Individuals who receive corticosteroids should be monitored for the development of new opportunistic infections, especially candidiasis [
         <a href="#rid39">
          39-42
         </a>
         ]. In an observational study of 174 patients with PCP, adjunctive corticosteroids increased the likelihood of subsequent esophageal candidiasis [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H23513321">
         <span class="h3">
          Adverse reactions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several of the antimicrobial regimens used to treat PCP are associated with significant side effects. A change in regimen may be needed for patients who develop severe adverse reactions (eg, Stevens Johnson syndrome with TMP-SMX, pancreatitis or renal failure with
         <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">
          pentamidine
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          TMP-SMX
         </strong>
         – Adverse reactions to TMP-SMX are common in patients being treated for PCP [
         <a href="#rid43">
          43
         </a>
         ]. Reactions can range from mild to severe and include gastrointestinal intolerance, photosensitivity, rash, and fever. Laboratory testing can reveal leukopenia and marked hyperkalemia, as well as evidence of acute kidney injury and hepatotoxicity [
         <a href="#rid44">
          44
         </a>
         ]. Sulfonamides should be immediately discontinued if any of the following conditions are present [
         <a href="#rid45">
          45
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Persistent rash and/or fever for more than five days
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Absolute neutrophil count &lt;500 cells/mm
         <sup>
          3
         </sup>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hypotension
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Intractable hyperkalemia
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Fever and flu-like symptoms, followed by conjunctival irritation, mucous membrane involvement, painful skin, target lesions, blistering, or desquamation of the skin
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We try to continue treatment in patients who have adverse reactions to TMP-SMX that are not life threatening [
         <a href="#rid9">
          9
         </a>
         ]. Antihistamines may be helpful in controlling minor reactions. Hydration or sodium polystyrene can be used to treat hyperkalemia caused by the renal tubular resorption of potassium. A more detailed discussion on adverse reactions to TMP-SMX is found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/493.html" rel="external">
          "Trimethoprim-sulfamethoxazole: An overview", section on 'Adverse effects and precautions'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          TMP-dapsone
         </strong>
         – Side effects of TMP-dapsone include gastrointestinal upset, rash, fever, hemolytic anemia, and methemoglobinemia. Laboratory testing can also reveal neutropenia, hyperkalemia, and transaminase elevations. An interaction between
         <a class="drug drug_general" data-topicid="10024" href="/z/d/drug information/10024.html" rel="external">
          trimethoprim
         </a>
         and
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          dapsone
         </a>
         appears to increase the levels of both drugs in patients being treated for PCP, and this may increase the risk of side effects such as anemia and methemoglobinemia [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clindamycin-primaquine
         </strong>
         – Side effects include rash, fever, diarrhea (including
         <em>
          Clostridioides difficile
         </em>
         -associated colitis), hemolytic anemia, neutropenia, and methemoglobinemia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8957" href="/z/d/drug information/8957.html" rel="external">
          Atovaquone
         </a>
         – The most common side effect is gastrointestinal distress. Other adverse reactions include fever and transaminase elevations. Rash may also occur, but is less common than with other regimens.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">
          Pentamidine
         </a>
         – Adverse reactions occur in up to 70 percent of patients and include nausea, taste disturbance, cardiac arrhythmias, hyperkalemia, nephrotoxicity, pancreatitis, hypokalemia, hypocalcemia, hypoglycemia, and hyperglycemia. Patients can develop permanent insulin-requiring diabetes mellitus after treatment with pentamidine [
         <a href="#rid47">
          47
         </a>
         ]. The nephrotoxicity of pentamidine is cumulative and is usually evidenced by a gradual increase in the creatinine concentration over the course of therapy. Concomitant use of other nephrotoxic drugs such as amphotericin B, aminoglycosides, and
         <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">
          foscarnet
         </a>
         potentiate the renal toxicity of pentamidine. Certain adverse events, particularly hypoglycemia and hypotension, may be life threatening.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H25052109">
         <span class="h3">
          Treatment failure
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who do not show any improvement (eg, tachypnea, hypoxemia) after four to eight days of therapy are considered treatment failures [
         <a href="#rid9">
          9
         </a>
         ]. Treatment failure may be due to the severity of disease at the time of diagnosis or to a concurrent infection that was not previously identified. It is possible that
         <em>
          P. jirovecii
         </em>
         can develop mutations associated with resistance to sulfa drugs; however, the impact of drug resistance on treatment outcomes has not been established [
         <a href="#rid2">
          2,3
         </a>
         ].
        </p>
        <p>
         Our approach to treatment failure is as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We modify the treatment regimen for patients failing therapy, especially those with severe disease and those who do not improve after eight days. However, this approach is based upon clinical experience and the findings of uncontrolled studies, since there are no controlled clinical trials to guide whether to continue or change initial therapy. Examples of treatment modifications include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If a patient progresses to severe disease while receiving oral therapy, we administer an IV regimen. For those receiving oral TMP-SMX, we change to IV TMP-SMX. Patients unable to tolerate TMP-SMX should be switched to clindamycin-primaquine. (See
         <a class="local">
          'Preferred regimen'
         </a>
         above and
         <a class="local">
          'Alternative regimens for severe disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients failing therapy with an alternative regimen, we determine if desensitization and changing to TMP-SMX is an option. (See
         <a class="local">
          'Desensitization for patients with a sulfa allergy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For those failing therapy with intravenous TMP-SMX, we initiate clindamycin-primaquine based upon the results of uncontrolled studies that suggest this regimen improves clinical outcomes when used as salvage therapy for the treatment of PCP [
         <a href="#rid8">
          8,16,48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with treatment failure should be evaluated for a concurrent infection since approximately 15 percent of patients with PCP will have more than one opportunistic infection. This may involve more invasive testing such as bronchoalveolar lavage. For patients with severe respiratory failure, empiric therapy directed at one or more of these infections may be indicated while the results of diagnostic tests are pending. A more detailed discussion of respiratory infections in patients with HIV is found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3704.html" rel="external">
          "Epidemiology, clinical presentation, and diagnosis of Pneumocystis pulmonary infection in patients with HIV", section on 'Differential diagnosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3721.html" rel="external">
          "Evaluation of pulmonary symptoms in persons with HIV", section on 'Invasive tests'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We initiate adjunctive corticosteroids if a patient’s respiratory status worsens and they require supplemental oxygen. Some patients may be stable initially (eg, mild disease), and then worsen clinically two to three days after starting anti-
         <em>
          Pneumocystis
         </em>
         therapy. Such patients typically have an increase in the alveolar-arterial oxygen gradient due to increased inflammation in the lungs as the organisms are killed. However, there are no controlled studies evaluating the use of corticosteroids in this setting. (See
         <a class="local">
          'Use of corticosteroids'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H536523970">
         <span class="h3">
          Respiratory failure
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who show progressive respiratory failure (eg, increased respiratory rate, worsening oxygen saturation) may require mechanical ventilatory support. For such patients, low tidal volumes and plateau pressures should be used given the potential presence of pneumatoceles, which increase the risk of pneumothorax [
         <a href="#rid49">
          49
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1640.html" rel="external">
          "Overview of initiating invasive mechanical ventilation in adults in the intensive care unit"
         </a>
         .)
        </p>
        <p>
         Patients with respiratory failure should also be assessed for pneumothorax since individuals with PCP are at risk for pneumothorax, both spontaneously or in the setting of mechanical ventilation [
         <a href="#rid50">
          50-52
         </a>
         ]. Such patients who develop pneumothorax in the setting of mechanical ventilation have a poor prognosis [
         <a href="#rid50">
          50
         </a>
         ]. A discussion on the management of pneumothorax in patients with HIV is found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/117242.html" rel="external">
          "Clinical presentation and diagnosis of pneumothorax"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H25051059">
         <span class="h2">
          Timing of ART initiation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients who present with PCP are not receiving ART at the time of their diagnosis. For such patients, we recommend ART be initiated within two weeks of starting PCP treatment [
         <a href="#rid9">
          9
         </a>
         ], preferably as soon as they are stable on PCP treatment. The use of early versus deferred ART was supported in a trial that enrolled 282 patients who presented with an opportunistic infection (OI), of whom the majority (63 percent) had PCP. Patients were randomly assigned to early ART (initiation within two weeks of starting OI therapy) or deferred ART (initiation after completing OI therapy) [
         <a href="#rid53">
          53
         </a>
         ]. Early therapy reduced the risk of AIDS progression and death by almost half, and was not associated with an increase in adverse events or an increase in the incidence of immune reconstitution inflammatory syndromes (IRIS). (See
         <a class="medical medical_review" href="/z/d/html/3762.html" rel="external">
          "Immune reconstitution inflammatory syndrome"
         </a>
         .)
        </p>
        <p>
         A detailed discussion on selecting an antiretroviral regimen is found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3773.html" rel="external">
          "Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H887410988">
         <span class="h2">
          Secondary prophylaxis
         </span>
         <span class="headingEndMark">
          —
         </span>
         After completing an initial 21-day course of treatment, patients should continue to receive antimicrobial therapy at a reduced dose to prevent recurrent infection (ie, secondary prophylaxis). The risk of developing recurrent PCP without secondary prophylaxis is 60 to 70 percent per year in patients who are not receiving ART [
         <a href="#rid54">
          54
         </a>
         ]. The antimicrobial regimens used for secondary prophylaxis are the same as those used to prevent initial infection and are described below. (See
         <a class="local">
          'Regimens for prophylaxis'
         </a>
         below.)
        </p>
        <p>
         Secondary prophylaxis can be discontinued in patients receiving ART if they have an undetectable viral load and a rise in their CD4 count to ≥200 cells/microL for at least three months. Discontinuing prophylaxis is also reasonable if the CD4 count is between 100 to 200 cells/microL and the HIV ribonucleic acid (RNA) remains below the limit of detection for about six months. Several studies have evaluated when prophylaxis can be discontinued [
         <a href="#rid55">
          55-58
         </a>
         ]. As an example, in a randomized trial of 113 patients with HIV with prior PCP on ART, secondary prophylaxis was safely discontinued after the CD4 cell count had increased to &gt;200 cells/microL for more than three months [
         <a href="#rid56">
          56
         </a>
         ]. Among the 60 patients who discontinued prophylaxis, there were no episodes of PCP during a median follow-up of 12 months (95% CI 0 to 4.5 episodes per 100 person-years).
        </p>
        <p>
         It is unclear if prophylaxis should be discontinued in patients who were diagnosed with PCP when their CD4 count was ≥200 cells/microL. We discuss the option of discontinuing PCP prophylaxis with individuals who have achieved virologic suppression for a period of time (eg, at least three to six months), since control of HIV viremia improves immune function independent of the absolute CD4 cell count [
         <a href="#rid59">
          59,60
         </a>
         ]. However, if PCP occurs at a CD4 count &gt;200 cells/microL while on ART, it may be prudent to continue lifelong prophylaxis.
        </p>
        <p class="headingAnchor" id="H2384560850">
         <span class="h1">
          PREVENTING INITIAL INFECTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with advanced immune suppression are at risk for developing
         <em>
          Pneumocystis
         </em>
         pneumonia (PCP). PCP is most likely to occur in patients who have a CD4 count &lt;200 cells/microL and are not receiving antiretroviral therapy (ART). A more detailed discussion of risk factors for PCP is found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3704.html" rel="external">
          "Epidemiology, clinical presentation, and diagnosis of Pneumocystis pulmonary infection in patients with HIV", section on 'Epidemiology'
         </a>
         .)
        </p>
        <p>
         The most effective way to prevent PCP is by improving immune function through use of antiretroviral therapy (ART). Antimicrobial agents should be administered for prophylaxis while awaiting immune recovery. (See
         <a class="local">
          'Initiating antiretroviral therapy'
         </a>
         below and
         <a class="local">
          'Indications for antimicrobial prophylaxis'
         </a>
         below and
         <a class="local">
          'Regimens for prophylaxis'
         </a>
         below.)
        </p>
        <p>
         The risk of developing infection may also be reduced by avoiding exposure to
         <em>
          P. jirovecii
         </em>
         . As an example, we avoid having hospitalized patients with PCP share rooms with other immunocompromised patients since there are data to suggest that person-to-person transmission of PCP can occur [
         <a href="#rid61">
          61
         </a>
         ]. However, there is no clear evidence that isolating patients with PCP will prevent transmission. A more detailed discussion on the transmission of PCP is found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3704.html" rel="external">
          "Epidemiology, clinical presentation, and diagnosis of Pneumocystis pulmonary infection in patients with HIV", section on 'Pathogenesis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H364876999">
         <span class="h2">
          Initiating antiretroviral therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most effective way to prevent PCP is by improving the immune system through use of ART. Thus, antiretroviral therapy should be initiated in all patients at risk of developing PCP. Immune recovery reduces the risk of developing PCP and allows prophylaxis to be discontinued. (See
         <a class="local">
          'Indications for antimicrobial prophylaxis'
         </a>
         below and
         <a class="local">
          'Discontinuing primary prophylaxis'
         </a>
         below.)
        </p>
        <p>
         A detailed discussion on selecting an antiretroviral regimen is found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3773.html" rel="external">
          "Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H436005707">
         <span class="h2">
          Antimicrobial prophylaxis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antimicrobial prophylaxis reduces the risk of developing PCP ninefold in patients who have a CD4 counts &lt;200 cells/microL and are not on ART [
         <a href="#rid54">
          54
         </a>
         ]. Prophylaxis is also associated with decreased health care costs and decreased mortality in those who develop infection [
         <a href="#rid54">
          54,62,63
         </a>
         ]. The most common reasons for failure of prophylaxis are nonadherence and/or a very low CD4 count (&lt;50 cells/microL) [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2384560868">
         <span class="h3">
          Indications for antimicrobial prophylaxis
         </span>
         <span class="headingEndMark">
          —
         </span>
         We agree with guidelines that recommend primary PCP prophylaxis for patients with any of the following [
         <a href="#rid9">
          9
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CD4 count &lt;200 cells/microL
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CD4 count percentage &lt;14 percent
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CD4 cell count between 200 and 250 cells/microL when frequent monitoring (eg, every three months) of CD4 cell counts is not possible
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We also administer PCP prophylaxis to individuals with a history of an AIDS-defining illness if they have not initiated ART or are
         <strong>
          not
         </strong>
         virologically suppressed on an ART regimen.
        </p>
        <p>
        </p>
        <p>
         We would
         <strong>
          not
         </strong>
         initiate prophylaxis based on the CD4 count criteria above in patients who meet criteria for discontinuation of prophylaxis (prolonged viral suppression and CD4 count between 100 and 200 cells/microL) (see
         <a class="local">
          'Discontinuing primary prophylaxis'
         </a>
         below). This approach is supported by an observational study of 23,412 patients receiving ART where 253 cases of PCP occurred over approximately five years [
         <a href="#rid58">
          58
         </a>
         ]. Antimicrobial prophylaxis significantly reduced the risk of developing PCP in patients who had a CD4 count &lt;100 cells/microL (adjusted incidence rate ratio 0.41, 95% CI 0.27-0.60). However, among patients with a CD4 count between 100 to 200 cells/microL and a viral load &lt;400 copies/mL, there was no significant difference in the incidence of PCP among those who did or did not receive antimicrobial prophylaxis (2.1 versus 1.2 cases per 1000 person years of follow-up).
        </p>
        <p class="headingAnchor" id="H2384560874">
         <span class="h3">
          Regimens for prophylaxis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several oral regimens are available for PCP prophylaxis  (
         <a class="graphic graphic_table graphicRef79988" href="/z/d/graphic/79988.html" rel="external">
          table 2
         </a>
         ). Which regimen to use, and the recommended dose, are influenced by concurrent or prior infection with toxoplasmosis.
        </p>
        <p>
         There have been many trials comparing the efficacy of different regimens for PCP prophylaxis [
         <a href="#rid12">
          12,13,64-67
         </a>
         ]. Taken together, they suggest that TMP-SMX is the most effective agent for prophylaxis in patients who can tolerate it. This was best illustrated in a meta-analysis of 35 studies of PCP prophylaxis in 6583 patients [
         <a href="#rid64">
          64
         </a>
         ]. TMP-SMX was superior to
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          dapsone
         </a>
         or aerosolized
         <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">
          pentamidine
         </a>
         for the prevention of PCP. However, there was no statistically significant survival advantage seen in those taking TMP-SMX compared with alternative agents.
        </p>
        <p class="headingAnchor" id="H1244898905">
         <span class="h4">
          Patients without a sulfa allergy
         </span>
         <span class="headingEndMark">
          —
         </span>
         We recommend
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         (TMP-SMX) as the treatment of choice for primary PCP prophylaxis in patients without a history of sulfa allergy. TMP-SMX also decreases this risk of toxoplasmosis and bacterial infections (including many respiratory bacterial infections) [
         <a href="#rid64">
          64,68,69
         </a>
         ].
        </p>
        <p>
         The dose of TMP-SMX used for PCP prophylaxis depends upon the patient’s risk for developing toxoplasmosis. The doses listed above are for patients with normal renal function; dose modifications for renal impairment may be needed. Detailed dosing recommendations are available in the drug information monograph included within UpToDate.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We administer one double-strength (DS) tablet daily to patients who require antimicrobial therapy to prevent toxoplasmosis (ie, those who have a CD4 count &lt;100 cells/microL and are IgG-positive for
         <em>
          Toxoplasma gondii
         </em>
         )
         <em>
          .
         </em>
         (See
         <a class="medical medical_review" href="/z/d/html/3710.html" rel="external">
          "Toxoplasmosis in patients with HIV", section on 'Primary prophylaxis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We administer one single-strength (SS) tablet daily to patients who do not require preventive therapy for toxoplasmosis. An alternative option for such patients is one DS tablet three times per week.
        </p>
        <p>
        </p>
        <p>
         We prefer the lower doses of TMP-SMX (eg, one SS tablet daily) in patients who do not require prophylaxis for toxoplasmosis since they have been found to be effective in preventing PCP and are better tolerated. Severe adverse effects requiring discontinuation of prophylaxis have been reported in 25 to 50 percent of patients receiving TMP-SMX [
         <a href="#rid12">
          12,66
         </a>
         ]. Approximately 40 percent of reactions that require discontinuation of TMP-SMX occur in the first month of therapy [
         <a href="#rid70">
          70
         </a>
         ]. (See
         <a class="local">
          'Adverse reactions'
         </a>
         above.)
        </p>
        <p>
         A randomized trial of 260 patients with HIV with a CD4 count &lt;200 cells/microL and no history of PCP compared daily treatment with TMP-SMX SS and TMP-SMX DS [
         <a href="#rid71">
          71
         </a>
         ]. Patients were followed for a median of 376 days, and no patient in either group developed PCP. However, more adverse reactions requiring treatment discontinuation were seen with the DS regimen (hazard ratio 1.4, 95% CI 0.95-2.02).
        </p>
        <p>
         Another randomized trial with a median follow-up of 22 months compared TMP-SMX DS daily with TMP-SMX DS three times per week in 2625 patients with HIV with a CD4 cell count &lt;200 cells/microL [
         <a href="#rid70">
          70
         </a>
         ]. In an intention-to-treat analysis, the yearly rate of PCP was similar in the two groups (3.5 versus 4.1 percent), although there were trends in favor of daily TMP-SMX for PCP, death, and bacterial pneumonia. However, discontinuation due to adverse events was more common in the daily therapy group (relative risk 2.14, 95% CI 1.73-2.66).
        </p>
        <p class="headingAnchor" id="H536525585">
         <span class="h4">
          Patients with a sulfa allergy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most patients unable to tolerate TMP-SMX, we use
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          dapsone
         </a>
         over
         <a class="drug drug_general" data-topicid="8957" href="/z/d/drug information/8957.html" rel="external">
          atovaquone
         </a>
         since it is a less expensive alternative and has comparable efficacy to atovaquone [
         <a href="#rid72">
          72,73
         </a>
         ]. Dapsone is a sulfone that is usually tolerated by persons who have adverse reactions to TMP-SMX [
         <a href="#rid12">
          12,13
         </a>
         ]. However, it may be prudent to avoid dapsone in patients who have had serious reactions to TMP-SMX (eg, Stevens Johnson syndrome/toxic epidermal necrolysis, rash with fever and systemic symptoms, serum sickness, or hemolytic anemia). (See
         <a class="medical medical_review" href="/z/d/html/2080.html" rel="external">
          "Sulfonamide allergy in HIV-uninfected patients", section on 'Cross-reactivity'
         </a>
         .)
        </p>
        <p>
         Aerosolized
         <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">
          pentamidine
         </a>
         (AP) is our last choice. Although AP is generally well tolerated, it is less effective than other regimens, requires special equipment, and is associated with transmission of other respiratory pathogens [
         <a href="#rid12">
          12,74
         </a>
         ]. In addition, AP is only effective locally; if dispersal of the aerosol does not reach all portions of the lungs, untreated areas remain at risk for PCP. Another option for TMP-SMX-allergic patients is desensitization to TMP-SMX. This is discussed below. (See
         <a class="local">
          'Desensitization for patients with a sulfa allergy'
         </a>
         below.)
        </p>
        <p>
         The alternative regimens are dosed as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          Dapsone
         </a>
         – The usual regimens for dapsone when used for PCP prophylaxis are:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          Dapsone
         </a>
         50 mg orally twice daily
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          Dapsone
         </a>
         100 mg orally once daily
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          Dapsone
         </a>
         50 mg orally once daily plus
         <a class="drug drug_general" data-topicid="9841" href="/z/d/drug information/9841.html" rel="external">
          pyrimethamine
         </a>
         50 mg once weekly and
         <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">
          leucovorin
         </a>
         25 mg one weekly
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          Dapsone
         </a>
         200 mg +
         <a class="drug drug_general" data-topicid="9841" href="/z/d/drug information/9841.html" rel="external">
          pyrimethamine
         </a>
         75 mg +
         <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">
          leucovorin
         </a>
         25 mg) orally once weekly
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          dapsone
         </a>
         is going to be prescribed, patients should be screened for glucose-6-phosphate dehydrogenase (G6PD) deficiency since patients with G6PD-deficiency are at risk for developing hemolytic anemia with dapsone (see
         <a class="medical medical_review" href="/z/d/html/7111.html" rel="external">
          "Diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency"
         </a>
         ). More detailed discussions of dapsone are found above. (See
         <a class="local">
          'Alternative regimens for mild to moderate disease'
         </a>
         above and
         <a class="local">
          'Adverse reactions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8957" href="/z/d/drug information/8957.html" rel="external">
          Atovaquone
         </a>
         – The dose of atovaquone suspension for PCP prophylaxis is 1500 mg daily given with food. More detailed discussions of atovaquone are found above. (See
         <a class="local">
          'Alternative regimens for mild to moderate disease'
         </a>
         above and
         <a class="local">
          'Adverse reactions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Aerosolized
         </strong>
         <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">
          pentamidine
         </a>
         <strong>
         </strong>
         – We administer AP for PCP prophylaxis only when other therapies cannot be used. The recommended dose of AP is 300 mg monthly via a nebulizer. AP is generally administered with two puffs of
         <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">
          albuterol
         </a>
         to reduce cough and bronchospasm.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Screening for active tuberculosis, including a baseline chest x-ray, should be performed before AP is administered since there is a concern about transmission of tuberculosis to health care workers and other patients through pentamidine-induced bronchospasm [
         <a href="#rid75">
          75,76
         </a>
         ]. In addition, AP should be administered in a negative pressure room in order to contain both aerosolized particles of the drug and any microbes that may be expectorated. When AP needs to be administered in an individual patient's hospital room, a HEPA-filtered containment tent should be used and the airflow into this room should be temporarily altered to negative pressure, if possible.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The major side effects of AP are cough and bronchospasm. The use of AP is also a risk factor for developing a pneumothorax [
         <a href="#rid77">
          77
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/117242.html" rel="external">
          "Clinical presentation and diagnosis of pneumothorax"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          Dapsone
         </a>
         alone and aerosolized
         <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">
          pentamidine
         </a>
         do not provide sufficient protection to prevent reactivation of
         <em>
          T. gondii
         </em>
         [
         <a href="#rid78">
          78
         </a>
         ]. Thus, additional agents must be used for patients who require treatment to prevent toxoplasmosis. A discussion on the prevention of toxoplasmosis is found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3710.html" rel="external">
          "Toxoplasmosis in patients with HIV", section on 'Prevention'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H419567111">
         <span class="h4">
          Patients being treated for toxoplasmosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who are receiving initial or maintenance therapy for toxoplasmosis with
         <a class="drug drug_general" data-topicid="9841" href="/z/d/drug information/9841.html" rel="external">
          pyrimethamine
         </a>
         /
         <a class="drug drug_general" data-topicid="9960" href="/z/d/drug information/9960.html" rel="external">
          sulfadiazine
         </a>
         do not require additional preventive therapy for PCP. (See
         <a class="medical medical_review" href="/z/d/html/3710.html" rel="external">
          "Toxoplasmosis in patients with HIV", section on 'Preferred regimens'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H536524412">
         <span class="h4">
          Pregnant women
         </span>
         <span class="headingEndMark">
          —
         </span>
         A detailed discussion on the prevention of PCP in pregnant women is found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/13972.html" rel="external">
          "Prenatal evaluation of women with HIV in resource-rich settings", section on 'Chemoprophylaxis for opportunistic infections'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2384560994">
         <span class="h3">
          Discontinuing primary prophylaxis
         </span>
        </p>
        <p class="headingAnchor" id="H3338710840">
         <span class="h4">
          CD4 count &gt;200 cells/microl
         </span>
         <span class="headingEndMark">
          —
         </span>
         We discontinue primary PCP prophylaxis in patients who are receiving ART and have an undetectable viral load if the CD4 count ≥200 cells/microL for
         <strong>
          three
         </strong>
         months or longer. This recommendation is consistent with guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV [
         <a href="#rid9">
          9
         </a>
         ] and is supported by several studies suggesting a low risk of PCP in this population [
         <a href="#rid79">
          79-82
         </a>
         ]. As an example, in a meta-analysis that evaluated 12 studies with 3035 subjects who discontinued primary PCP prophylaxis following immune reconstitution on ART (mainly defined by CD4 cell count &gt;200 cells/microL), seven cases of PCP occurred with a cumulative incidence of 0.23 percent (95% CI 0.09-0.48) [
         <a href="#rid82">
          82
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2838958393">
         <span class="h4">
          CD4 count 100-200 cells/microl
         </span>
         <span class="headingEndMark">
          —
         </span>
         We discontinue primary PCP prophylaxis in patients with a CD4 count between 100 and 200 cells/microL if they are receiving ART and have had an undetectable viral load for
         <strong>
          six
         </strong>
         months or longer. The risk of PCP appears extremely low in such patients if virologic suppression is maintained [
         <a href="#rid58">
          58,83
         </a>
         ]. In a cohort study that followed approximately 5000 patients for a median duration of 3.5 years, no cases of PCP occurred in patients who were virologically suppressed and discontinued prophylaxis with a CD4 count between 100 and 200 cells/microL (95% CI 0.0-2.7 cases per 1000 person-years of follow-up) [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2334250752">
         <span class="h4">
          CD4 count &lt;100 cells/microL
         </span>
         <span class="headingEndMark">
          —
         </span>
         We generally prefer to continue primary PCP prophylaxis in patients with a CD4 count &lt;100 cells/microL. This recommendation is consistent with guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV [
         <a href="#rid9">
          9
         </a>
         ]. Since most patients starting on ART with low CD4 cell counts gain on average 100 to 200 cells/microL per year, they usually meet the threshold to consider discontinuation (ie, CD4 cell count ≥100 cells/microL and prolonged virologic suppression) within several months. However, if patients are receiving ART, have had an undetectable viral load for six months or longer, and the CD4 cell count remains below 100 cells/microL, it may be reasonable to discontinue primary prophylaxis, although we do not routinely do this because the risk of PCP is highest at these CD4 cell count levels.
        </p>
        <p>
         In a cohort study that followed approximately 5000 patients on ART for a median duration of 4.3 years, there was no significant difference in incidence of PCP in patients who stopped primary PCP prophylaxis when CD4 &gt;200 cells/microL compared with those who stopped when viral load was undetectable for three months or longer, regardless of CD4 cell count (adjusted hazard ratio 0.8, 95% CI 0.6-1.1) [
         <a href="#rid84">
          84
         </a>
         ]. However, patients with CD4 cell count &lt;100 cells/microL comprised 67 percent of new PCP cases, suggesting that CD4 counts &lt;100 cells/microL is still a risk factor for PCP even in those with an undetectable viral load.
        </p>
        <p class="headingAnchor" id="H1521584211">
         <span class="h3">
          Restarting primary prophylaxis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prophylaxis should be reintroduced if:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CD4 count falls to &lt;100 cells/microL
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CD4 count falls between 100-200 cells/microL and the viral load becomes detectable
        </p>
        <p>
        </p>
        <p>
         These recommendations reflect the patient populations that are at highest risk of PCP infection. We do not recommend restarting primary prophylaxis in patients with CD4 counts between 100 to 200 cells/microL if their viral load has remained undetectable for six months or longer. (See
         <a class="local">
          'Indications for antimicrobial prophylaxis'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H549880787">
         <span class="h1">
          DESENSITIZATION FOR PATIENTS WITH A SULFA ALLERGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          Trimethoprim-sulfamethoxazole
         </a>
         (TMP-SMX) can be reintroduced to certain individuals with a history of an isolated cutaneous reaction to sulfa (ie, without systemic involvement). More detailed discussions on the manifestations and management of sulfonamide allergies are found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2080.html" rel="external">
          "Sulfonamide allergy in HIV-uninfected patients"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/493.html" rel="external">
          "Trimethoprim-sulfamethoxazole: An overview", section on 'Adverse effects and precautions'
         </a>
         .)
        </p>
        <p>
         For such patients, we attempt to "desensitize" the patient to TMP-SMX using a gradual dose escalation. We administer the following desensitization protocol using TMP-SMX pediatric suspension (TMP 8 mg/mL and SMX 40 mg/mL) [
         <a href="#rid85">
          85
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Day 1: 1.25 mL once
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Day 2: 1.25 mL twice daily
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Day 3: 1.25 mL three times daily
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Day 4: 2.5 mL twice daily
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Day 5: 2.5 mL three times daily
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Day 6: one SS tablet
        </p>
        <p>
        </p>
        <p>
         One SS tablet daily can be used for prophylaxis. For those who require full treatment doses, the dose can then be gradually increased over several days (see
         <a class="local">
          'Preferred regimen'
         </a>
         above).
        </p>
        <p>
         For example, the protocol above can be continued as below:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Day 7: one SS tablet three times daily
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Day 8: One DS tablet twice daily
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Day 9: Two DS tablets twice daily
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Day 10: Two DS tablets three times daily (for a target dose of approximately 15 mg/kg/day for a 60 kg person)
        </p>
        <p>
        </p>
        <p>
         An alternative PCP regimen should be used until a patient is able to tolerate treatment doses. (See
         <a class="local">
          'Alternative regimens'
         </a>
         above.)
        </p>
        <p>
         Although a majority of patients may be able to tolerate TMP-SMX when rechallenged with the full dose [
         <a href="#rid85">
          85,86
         </a>
         ], dose escalation over one to two weeks reduces the risk of developing an adverse reaction [
         <a href="#rid85">
          85,87
         </a>
         ]. As an example, a randomized trial compared dose escalation of TMP-SMX with immediate resumption of a SS tablet daily in 190 patients with HIV who had previously discontinued TMP-SMX for an adverse reaction [
         <a href="#rid85">
          85
         </a>
         ]. The trial was stopped early by a monitoring board since more patients who received dose escalation remained on TMP-SMX at six months (75 versus 57 percent).
        </p>
        <p>
         Desensitization to TMP-SMX is reviewed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2080.html" rel="external">
          "Sulfonamide allergy in HIV-uninfected patients", section on 'Protocols for past rash/fever'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1235734920">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/111612.html" rel="external">
          "Society guideline links: Opportunistic infections in adults with HIV"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H202626719">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/17209.html" rel="external">
          "Patient education: Pneumocystis pneumonia (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H25052742">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Overview
         </strong>
         −
         <em>
          Pneumocystis jirovecii
         </em>
         pneumonia (formerly called
         <em>
          Pneumocystis carinii
         </em>
         pneumonia or PCP) is the most common opportunistic respiratory infection in patients with HIV. It typically occurs in patients with HIV with a CD4 count &lt;200 cells/microL who are not receiving antiretroviral therapy or appropriate prophylaxis. Antimicrobial therapy directed against
         <em>
          P. jiroveci
         </em>
         is the mainstay of treatment for PCP. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Approach to treatment
         </strong>
         − The approach to treatment (eg, the choice of agent, the mode of administration, and the use of adjunctive corticosteroids) is based upon the severity of disease. Preferred and alternative regimen dosing and duration are presented in the table  (
         <a class="graphic graphic_table graphicRef61052" href="/z/d/graphic/61052.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Preferred regimen'
         </a>
         above and
         <a class="local">
          'Alternative regimens'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Severe disease
         </strong>
         − For patients with severe disease, we recommend treatment with intravenous (IV)
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         (TMP-SMX) rather than IV
         <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">
          pentamidine
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_1" rel="external">
          Grade 1A
         </a>
         ). For patients with severe disease who are unable to take TMP-SMX, we suggest clindamycin-primaquine rather than IV pentamidine (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). However, for such patients who cannot take medications orally, pentamidine is the only IV option. If pentamidine is used, patients should be switched to a less toxic regimen as soon as they can tolerate oral therapy. (See
         <a class="local">
          'Severe disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Mild to moderate disease
         </strong>
         − For individuals with mild to moderate disease, we suggest treatment with oral TMP-SMX rather than oral trimethoprim-dapsone (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). For most individuals with mild to moderate disease who are unable to take TMP-SMX, we suggest
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          dapsone
         </a>
         plus
         <a class="drug drug_general" data-topicid="10024" href="/z/d/drug information/10024.html" rel="external">
          trimethoprim
         </a>
         or
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         plus
         <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">
          primaquine
         </a>
         rather than
         <a class="drug drug_general" data-topicid="8957" href="/z/d/drug information/8957.html" rel="external">
          atovaquone
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). Treatment with atovaquone for PCP should preferentially be limited to patients with mild disease, or to complete a course of therapy in patients improving on TMP-SMX who develop an adverse reaction and need to stop it. (See
         <a class="local">
          'Mild disease'
         </a>
         above and
         <a class="local">
          'Moderate disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Indications for hospitalization
         </strong>
         − Patients with PCP sometimes worsen after two to three days of therapy. In general, hospitalization for therapy is warranted in patients who need treatment with corticosteroids, initial treatment with IV
         <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">
          pentamidine
         </a>
         given the potential side effects of therapy (eg, hypoglycemia, hypotension), and patients for whom compliance with therapy or laboratory monitoring is likely to be difficult. (See
         <a class="local">
          'Indications for hospitalization'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Use of adjunctive corticosteroids
         </strong>
         − For patients with moderate to severe disease (eg, a partial pressure of oxygen of &lt;70 mmHg on room air and/or an alveolar-arterial (A-a) oxygen gradient of ≥35 mmHg), we recommend initiating corticosteroids (
         <a class="grade" href="https:///uptodate/show/grade_1" rel="external">
          Grade 1A
         </a>
         ). We also administer corticosteroids to patients with clear evidence of hypoxemia (eg, resting room air oxygen saturation &lt;92 percent). Corticosteroids should be administered concurrently with anti-
         <em>
          Pneumocystis
         </em>
         therapy in this setting to decrease the incidence of mortality and respiratory failure associated with PCP. (See
         <a class="local">
          'Use of corticosteroids'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Approach to pregnant patients
         </strong>
         − TMP-SMX is the preferred therapy for PCP in pregnant women. If an alternative therapy must be used, trimethoprim-dapsone can be administered since there is clinical experience with this regimen in pregnancy. (See
         <a class="local">
          'Pregnancy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monitoring patients on treatment
         </strong>
         − Patients should be monitored for adverse events related to their treatment regimen and their response to therapy. A change in regimen may be needed for patients who develop severe adverse reactions (eg, Stevens-Johnson syndrome with TMP-SMX, pancreatitis, or renal failure with
         <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">
          pentamidine
         </a>
         ). We also modify the treatment regimen for patients failing therapy (no improvement after four to eight days of therapy), especially those with severe disease who do not improve after eight days. (See
         <a class="local">
          'Monitoring patients on treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Timing of ART initiation
         </strong>
         − For patients with PCP who are not receiving antiretroviral therapy (ART) at the time of their diagnosis, we recommend ART be initiated within two weeks of PCP treatment (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). Early ART (versus starting therapy after PCP treatment) can reduce the risk of AIDS progression and death in patients presenting with PCP. (See
         <a class="local">
          'Timing of ART initiation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Secondary prophylaxis
         </strong>
         − After completing their initial 21-day course of treatment, patients should continue to receive antimicrobial therapy at a reduced dose to prevent recurrent infection (ie, secondary prophylaxis). Secondary prophylaxis can be discontinued in patients receiving ART if they have an undetectable viral load and a rise in their CD4 count to ≥200 cells/microL for at least three months. (See
         <a class="local">
          'Secondary prophylaxis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preventing initial infection
         </strong>
         − The most effective way to prevent PCP is by improving the immune system through use of ART. (See
         <a class="local">
          'Preventing initial infection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Indications for prophylaxis
         </strong>
         − We administer PCP prophylaxis to patients with any of the following characteristics:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         CD4 count &lt;200 cells/microL
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         CD4 percentage &lt;14 percent
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         History of an AIDS-defining illness if they have not initiated ART or a
         <strong>
          re not
         </strong>
         virologically suppressed while receiving an ART regimen.
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         CD4 count between 200 and 250 cells/microL when frequent monitoring of CD4 counts is not possible. (See
         <a class="local">
          'Indications for antimicrobial prophylaxis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Regimens for prophylaxis
         </strong>
         − For patients who meet criteria for PCP prophylaxis, we recommend TMP-SMX rather than
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          dapsone
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_1" rel="external">
          Grade 1A
         </a>
         ). For individuals who cannot take TMP-SMX or dapsone,
         <a class="drug drug_general" data-topicid="8957" href="/z/d/drug information/8957.html" rel="external">
          atovaquone
         </a>
         is preferred over aerosolized
         <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">
          pentamidine
         </a>
         (
         <a class="graphic graphic_table graphicRef79988" href="/z/d/graphic/79988.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Regimens for prophylaxis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Discontinuation of prophylaxis
         </strong>
         − We discontinue primary PCP prophylaxis in patients receiving ART if they have an undetectable viral load and a rise in their CD4 count to ≥200 cells/microL for at least three months or have prolonged viral suppression and a CD4 count between 100 and 200 cells/microL. (See
         <a class="local">
          'Discontinuing primary prophylaxis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8513564">
         <span class="h1">
          ACKNOWLEDGMENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Patricia Tietjen, MD, who contributed to an earlier version of this topic review.
        </p>
        <p>
         UpToDate also gratefully acknowledges John G Bartlett, MD (deceased), who contributed as Section Editor on earlier versions of this topic and was a founding Editor-in-Chief for UpToDate in Infectious Diseases.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Safrin S, Finkelstein DM, Feinberg J, et al. Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized, trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. ACTG 108 Study Group. Ann Intern Med 1996; 124:792.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kazanjian P, Armstrong W, Hossler PA, et al. Pneumocystis carinii mutations are associated with duration of sulfa or sulfone prophylaxis exposure in AIDS patients. J Infect Dis 2000; 182:551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Navin TR, Beard CB, Huang L, et al. Effect of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of P carinii pneumonia in patients with HIV-1: a prospective study. Lancet 2001; 358:545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wharton JM, Coleman DL, Wofsy CB, et al. Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective randomized trial. Ann Intern Med 1986; 105:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sattler FR, Cowan R, Nielsen DM, Ruskin J. Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective, noncrossover study. Ann Intern Med 1988; 109:280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klein NC, Duncanson FP, Lenox TH, et al. Trimethoprim-sulfamethoxazole versus pentamidine for Pneumocystis carinii pneumonia in AIDS patients: results of a large prospective randomized treatment trial. AIDS 1992; 6:301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Noskin GA, Murphy RL, Black JR, Phair JP. Salvage therapy with clindamycin/primaquine for Pneumocystis carinii pneumonia. Clin Infect Dis 1992; 14:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smego RA Jr, Nagar S, Maloba B, Popara M. A meta-analysis of salvage therapy for Pneumocystis carinii pneumonia. Arch Intern Med 2001; 161:1529.
          </a>
         </li>
         <li class="breakAll">
          Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/whats-new-guidelines (Accessed on April 26, 2018).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Butler-Laporte G, Smyth E, Amar-Zifkin A, et al. Low-Dose TMP-SMX in the Treatment of Pneumocystis jirovecii Pneumonia: A Systematic Review and Meta-analysis. Open Forum Infect Dis 2020; 7:ofaa112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sohani ZN, Butler-Laporte G, Aw A, et al. Low-dose trimethoprim-sulfamethoxazole for the treatment of Pneumocystis jirovecii pneumonia (LOW-TMP): protocol for a phase III randomised, placebo-controlled, dose-comparison trial. BMJ Open 2022; 12:e053039.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bozzette SA, Finkelstein DM, Spector SA, et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med 1995; 332:693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beumont MG, Graziani A, Ubel PA, MacGregor RR. Safety of dapsone as Pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with allergy to trimethoprim/sulfamethoxazole. Am J Med 1996; 100:611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kovacs JA, Gill VJ, Meshnick S, Masur H. New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia. JAMA 2001; 286:2450.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Falloon J, Kovacs J, Hughes W, et al. A preliminary evaluation of 566C80 for the treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome. N Engl J Med 1991; 325:1534.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Helweg-Larsen J, Benfield T, Atzori C, Miller RF. Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study. J Antimicrob Chemother 2009; 64:1282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim T, Kim SH, Park KH, et al. Clindamycin-primaquine versus pentamidine for the second-line treatment of pneumocystis pneumonia. J Infect Chemother 2009; 15:343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang YS, Liu CE, Lin SP, et al. Echinocandins as alternative treatment for HIV-infected patients with Pneumocystis pneumonia. AIDS 2019; 33:1345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ewald H, Raatz H, Boscacci R, et al. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection. Cochrane Database Syst Rev 2015; :CD006150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montaner JS, Lawson LM, Levitt N, et al. Corticosteroids prevent early deterioration in patients with moderately severe Pneumocystis carinii pneumonia and the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1990; 113:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bozzette SA, Sattler FR, Chiu J, et al. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N Engl J Med 1990; 323:1451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gagnon S, Boota AM, Fischl MA, et al. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A double-blind, placebo-controlled trial. N Engl J Med 1990; 323:1444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           National Institutes of Health-University of California Expert Panel for Corticosteroids as Adjunctive Therapy for Pneumocystis Pneumonia. Consensus statement on the use of corticosteroids as adjunctive therapy for pneumocystis pneumonia in the acquired immunodeficiency syndrome. N Engl J Med 1990; 323:1500.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LaRocco A Jr, Amundson DE, Wallace MR, et al. Corticosteroids for Pneumocystis carinii pneumonia with acute respiratory failure. Experience with rescue therapy. Chest 1992; 102:892.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Czeizel AE, Rockenbauer M, Sørensen HT, Olsen J. The teratogenic risk of trimethoprim-sulfonamides: a population based case-control study. Reprod Toxicol 2001; 15:637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hernández-Díaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000; 343:1608.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harstad TW, Little BB, Bawdon RE, et al. Embryofetal effects of pentamidine isethionate administered to pregnant Sprague-Dawley rats. Am J Obstet Gynecol 1990; 163:912.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antinori A, Maiuro G, Pallavicini F, et al. Prognostic factors of early fatal outcome and long-term survival in patients with Pneumocystis carinii pneumonia and acquired immunodeficiency syndrome. Eur J Epidemiol 1993; 9:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernandez P, Torres A, Miro JM, et al. Prognostic factors influencing the outcome in pneumocystis carinii pneumonia in patients with AIDS. Thorax 1995; 50:668.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wachter RM, Russi MB, Bloch DA, et al. Pneumocystis carinii pneumonia and respiratory failure in AIDS. Improved outcomes and increased use of intensive care units. Am Rev Respir Dis 1991; 143:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dickson SJ, Batson S, Copas AJ, et al. Survival of HIV-infected patients in the intensive care unit in the era of highly active antiretroviral therapy. Thorax 2007; 62:964.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Curtis JR, Yarnold PR, Schwartz DN, et al. Improvements in outcomes of acute respiratory failure for patients with human immunodeficiency virus-related Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 2000; 162:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller RF, Allen E, Copas A, et al. Improved survival for HIV infected patients with severe Pneumocystis jirovecii pneumonia is independent of highly active antiretroviral therapy. Thorax 2006; 61:716.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benfield TL, Helweg-Larsen J, Bang D, et al. Prognostic markers of short-term mortality in AIDS-associated Pneumocystis carinii pneumonia. Chest 2001; 119:844.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jensen AM, Lundgren JD, Benfield T, et al. Does cytomegalovirus predict a poor prognosis in Pneumocystis carinii pneumonia treated with corticosteroids? A note for caution. Chest 1995; 108:411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dworkin MS, Hanson DL, Navin TR. Survival of patients with AIDS, after diagnosis of Pneumocystis carinii pneumonia, in the United States. J Infect Dis 2001; 183:1409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Powell K, Davis JL, Morris AM, et al. Survival for patients With HIV admitted to the ICU continues to improve in the current era of combination antiretroviral therapy. Chest 2009; 135:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morris A, Wachter RM, Luce J, et al. Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia. AIDS 2003; 17:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nelson MR, Erskine D, Hawkins DA, Gazzard BG. Treatment with corticosteroids--a risk factor for the development of clinical cytomegalovirus disease in AIDS. AIDS 1993; 7:375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horsburgh CR Jr. Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. N Engl J Med 1991; 324:1332.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gallant JE, Chaisson RE, Moore RD. The effect of adjunctive corticosteroids for the treatment of Pneumocystis carinii pneumonia on mortality and subsequent complications. Chest 1998; 114:1258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martos A, Podzamczer D, Martinez-Lacasa J, et al. Steroids do not enhance the risk of developing tuberculosis or other AIDS-related diseases in HIV-infected patients treated for Pneumocystis carinii pneumonia. AIDS 1995; 9:1037.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Medina I, Mills J, Leoung G, et al. Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. N Engl J Med 1990; 323:776.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gordin FM, Simon GL, Wofsy CB, Mills J. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1984; 100:495.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bayard PJ, Berger TG, Jacobson MA. Drug hypersensitivity reactions and human immunodeficiency virus disease. J Acquir Immune Defic Syndr 1992; 5:1237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee BL, Medina I, Benowitz NL, et al. Dapsone, trimethoprim, and sulfamethoxazole plasma levels during treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome (AIDS). Evidence of drug interactions. Ann Intern Med 1989; 110:606.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liegl U, Bogner JR, Goebel FD. Insulin-dependent diabetes mellitus following pentamidine therapy in a patient with AIDS. Clin Investig 1994; 72:1027.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benfield T, Atzori C, Miller RF, Helweg-Larsen J. Second-line salvage treatment of AIDS-associated Pneumocystis jirovecii pneumonia: a case series and systematic review. J Acquir Immune Defic Syndr 2008; 48:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang L, Quartin A, Jones D, Havlir DV. Intensive care of patients with HIV infection. N Engl J Med 2006; 355:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pastores SM, Garay SM, Naidich DP, Rom WN. Review: pneumothorax in patients with AIDS-related Pneumocystis carinii pneumonia. Am J Med Sci 1996; 312:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosen MJ, Clayton K, Schneider RF, et al. Intensive care of patients with HIV infection: utilization, critical illnesses, and outcomes. Pulmonary Complications of HIV Infection Study Group. Am J Respir Crit Care Med 1997; 155:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tumbarello M, Tacconelli E, Pirronti T, et al. Pneumothorax in HIV-infected patients: role of Pneumocystis carinii pneumonia and pulmonary tuberculosis. Eur Respir J 1997; 10:1332.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One 2009; 4:e5575.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stansell JD, Osmond DH, Charlebois E, et al. Predictors of Pneumocystis carinii pneumonia in HIV-infected persons. Pulmonary Complications of HIV Infection Study Group. Am J Respir Crit Care Med 1997; 155:60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ledergerber B, Mocroft A, Reiss P, et al. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups. N Engl J Med 2001; 344:168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lopez Bernaldo de Quiros JC, Miro JM, Peña JM, et al. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98. N Engl J Med 2001; 344:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mussini C, Pezzotti P, Antinori A, et al. Discontinuation of secondary prophylaxis for Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients: a randomized trial by the CIOP Study Group. Clin Infect Dis 2003; 36:645.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE), Mocroft A, Reiss P, et al. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count &lt;200 cells/microL? Clin Infect Dis 2010; 51:611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swindells S, Evans S, Zackin R, et al. Predictive value of HIV-1 viral load on risk for opportunistic infection. J Acquir Immune Defic Syndr 2002; 30:154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaplan JE, Hanson DL, Jones JL, et al. Viral load as an independent risk factor for opportunistic infections in HIV-infected adults and adolescents. AIDS 2001; 15:1831.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kovacs JA, Masur H. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. N Engl J Med 2000; 342:1416.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dohn MN, Baughman RP, Vigdorth EM, Frame DL. Equal survival rates for first, second, and third episodes of Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. Arch Intern Med 1992; 152:2465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gallant JE, McAvinue SM, Moore RD, et al. The impact of prophylaxis on outcome and resource utilization in Pneumocystis carinii pneumonia. Chest 1995; 107:1018.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ioannidis JP, Cappelleri JC, Skolnik PR, et al. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch Intern Med 1996; 156:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fischl MA, Dickinson GM, La Voie L. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. JAMA 1988; 259:1185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schneider MM, Hoepelman AI, Eeftinck Schattenkerk JK, et al. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group. N Engl J Med 1992; 327:1836.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hardy WD, Feinberg J, Finkelstein DM, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021. N Engl J Med 1992; 327:1842.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirschtick RE, Glassroth J, Jordan MC, et al. Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary Complications of HIV Infection Study Group. N Engl J Med 1995; 333:845.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mermin J, Lule J, Ekwaru JP, et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet 2004; 364:1428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El-Sadr WM, Luskin-Hawk R, Yurik TM, et al. A randomized trial of daily and thrice-weekly trimethoprim-sulfamethoxazole for the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected persons. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). Clin Infect Dis 1999; 29:775.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schneider MM, Nielsen TL, Nelsing S, et al. Efficacy and toxicity of two doses of trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus. Dutch AIDS Treatment Group. J Infect Dis 1995; 171:1632.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El-Sadr WM, Murphy RL, Yurik TM, et al. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group. N Engl J Med 1998; 339:1889.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan C, Montaner J, Lefebvre EA, et al. Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides. J Infect Dis 1999; 180:369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirschel B, Lazzarin A, Chopard P, et al. A controlled study of inhaled pentamidine for primary prevention of Pneumocystis carinii pneumonia. N Engl J Med 1991; 324:1079.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beck-Sagué C, Dooley SW, Hutton MD, et al. Hospital outbreak of multidrug-resistant Mycobacterium tuberculosis infections. Factors in transmission to staff and HIV-infected patients. JAMA 1992; 268:1280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fischl MA, Uttamchandani RB, Daikos GL, et al. An outbreak of tuberculosis caused by multiple-drug-resistant tubercle bacilli among patients with HIV infection. Ann Intern Med 1992; 117:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Metersky ML, Colt HG, Olson LK, Shanks TG. AIDS-related spontaneous pneumothorax. Risk factors and treatment. Chest 1995; 108:946.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bucher HC, Griffith L, Guyatt GH, Opravil M. Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 15:104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaplan JE, Hanson DL, Navin TR, Jones JL. Risk factors for primary Pneumocystis carinii pneumonia in human immunodeficiency virus-infected adolescents and adults in the United States: reassessment of indications for chemoprophylaxis. J Infect Dis 1998; 178:1126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weverling GJ, Mocroft A, Ledergerber B, et al. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group. Lancet 1999; 353:1293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Furrer H, Egger M, Opravil M, et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. N Engl J Med 1999; 340:1301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trikalinos TA, Ioannidis JP. Discontinuation of Pneumocystis carinii prophylaxis in patients infected with human immunodeficiency virus: a meta-analysis and decision analysis. Clin Infect Dis 2001; 33:1901.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Egidio GE, Kravcik S, Cooper CL, et al. Pneumocystis jiroveci pneumonia prophylaxis is not required with a CD4+ T-cell count &lt; 200 cells/microl when viral replication is suppressed. AIDS 2007; 21:1711.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Atkinson A, Zwahlen M, Barger D, et al. Withholding Primary Pneumocystis Pneumonia Prophylaxis in Virologically Suppressed Patients With Human Immunodeficiency Virus: An Emulation of a Pragmatic Trial in COHERE. Clin Infect Dis 2021; 73:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leoung GS, Stanford JF, Giordano MF, et al. Trimethoprim-sulfamethoxazole (TMP-SMZ) dose escalation versus direct rechallenge for Pneumocystis Carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with previous adverse reaction to TMP-SMZ. J Infect Dis 2001; 184:992.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carr A, Penny R, Cooper DA. Efficacy and safety of rechallenge with low-dose trimethoprim-sulphamethoxazole in previously hypersensitive HIV-infected patients. AIDS 1993; 7:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Para MF, Finkelstein D, Becker S, et al. Reduced toxicity with gradual initiation of trimethoprim-sulfamethoxazole as primary prophylaxis for Pneumocystis carinii pneumonia: AIDS Clinical Trials Group 268. J Acquir Immune Defic Syndr 2000; 24:337.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3709 Version 49.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8610948" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized, trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. ACTG 108 Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10915088" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Pneumocystis carinii mutations are associated with duration of sulfa or sulfone prophylaxis exposure in AIDS patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11520525" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Effect of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of P carinii pneumonia in patients with HIV-1: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3521428" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3260759" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective, noncrossover study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1567574" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Trimethoprim-sulfamethoxazole versus pentamidine for Pneumocystis carinii pneumonia in AIDS patients: results of a large prospective randomized treatment trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1571426" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Salvage therapy with clindamycin/primaquine for Pneumocystis carinii pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11427101" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : A meta-analysis of salvage therapy for Pneumocystis carinii pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11427101" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : A meta-analysis of salvage therapy for Pneumocystis carinii pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32391402" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Low-Dose TMP-SMX in the Treatment of Pneumocystis jirovecii Pneumonia: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35863836" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Low-dose trimethoprim-sulfamethoxazole for the treatment of Pneumocystis jirovecii pneumonia (LOW-TMP): protocol for a phase III randomised, placebo-controlled, dose-comparison trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7854375" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8678080" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Safety of dapsone as Pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with allergy to trimethoprim/sulfamethoxazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11712941" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1944437" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : A preliminary evaluation of 566C80 for the treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19858161" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19856077" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Clindamycin-primaquine versus pentamidine for the second-line treatment of pneumocystis pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30932964" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Echinocandins as alternative treatment for HIV-infected patients with Pneumocystis pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25835432" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2190515" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Corticosteroids prevent early deterioration in patients with moderately severe Pneumocystis carinii pneumonia and the acquired immunodeficiency syndrome (AIDS)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2233917" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. California Collaborative Treatment Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2233916" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2136587" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Consensus statement on the use of corticosteroids as adjunctive therapy for pneumocystis pneumonia in the acquired immunodeficiency syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1516418" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Corticosteroids for Pneumocystis carinii pneumonia with acute respiratory failure. Experience with rescue therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11738517" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : The teratogenic risk of trimethoprim-sulfonamides: a population based case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11096168" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Folic acid antagonists during pregnancy and the risk of birth defects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2403167" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Embryofetal effects of pentamidine isethionate administered to pregnant Sprague-Dawley rats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8100199" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Prognostic factors of early fatal outcome and long-term survival in patients with Pneumocystis carinii pneumonia and acquired immunodeficiency syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7638811" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Prognostic factors influencing the outcome in pneumocystis carinii pneumonia in patients with AIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1990936" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Pneumocystis carinii pneumonia and respiratory failure in AIDS. Improved outcomes and increased use of intensive care units.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17517829" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Survival of HIV-infected patients in the intensive care unit in the era of highly active antiretroviral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10934059" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Improvements in outcomes of acute respiratory failure for patients with human immunodeficiency virus-related Pneumocystis carinii pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16601092" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Improved survival for HIV infected patients with severe Pneumocystis jirovecii pneumonia is independent of highly active antiretroviral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11243967" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Prognostic markers of short-term mortality in AIDS-associated Pneumocystis carinii pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7634876" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Does cytomegalovirus predict a poor prognosis in Pneumocystis carinii pneumonia treated with corticosteroids? A note for caution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11294675" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Survival of patients with AIDS, after diagnosis of Pneumocystis carinii pneumonia, in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18719058" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Survival for patients With HIV admitted to the ICU continues to improve in the current era of combination antiretroviral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12478071" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8097096" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Treatment with corticosteroids--a risk factor for the development of clinical cytomegalovirus disease in AIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2017230" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Mycobacterium avium complex infection in the acquired immunodeficiency syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9823998" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : The effect of adjunctive corticosteroids for the treatment of Pneumocystis carinii pneumonia on mortality and subsequent complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8527075" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Steroids do not enhance the risk of developing tuberculosis or other AIDS-related diseases in HIV-infected patients treated for Pneumocystis carinii pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2392131" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6230976" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1453334" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Drug hypersensitivity reactions and human immunodeficiency virus disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2784648" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Dapsone, trimethoprim, and sulfamethoxazole plasma levels during treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome (AIDS). Evidence of drug interactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7711409" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Insulin-dependent diabetes mellitus following pentamidine therapy in a patient with AIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18360286" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Second-line salvage treatment of AIDS-associated Pneumocystis jirovecii pneumonia: a case series and systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16837681" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Intensive care of patients with HIV infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8900387" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Review: pneumothorax in patients with AIDS-related Pneumocystis carinii pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9001291" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Intensive care of patients with HIV infection: utilization, critical illnesses, and outcomes. Pulmonary Complications of HIV Infection Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9192938" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Pneumothorax in HIV-infected patients: role of Pneumocystis carinii pneumonia and pulmonary tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19440326" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9001290" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Predictors of Pneumocystis carinii pneumonia in HIV-infected persons. Pulmonary Complications of HIV Infection Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11188837" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11172138" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12594647" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Discontinuation of secondary prophylaxis for Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients: a randomized trial by the CIOP Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20645862" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count&lt;200 cells/microL?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12045677" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Predictive value of HIV-1 viral load on risk for opportunistic infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11579245" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Viral load as an independent risk factor for opportunistic infections in HIV-infected adults and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10805828" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1456858" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Equal survival rates for first, second, and third episodes of Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7705108" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : The impact of prophylaxis on outcome and resource utilization in Pneumocystis carinii pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8546551" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3257532" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1360145" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1448121" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7651475" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary Complications of HIV Infection Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15488218" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10589887" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : A randomized trial of daily and thrice-weekly trimethoprim-sulfamethoxazole for the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected persons. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7769306" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Efficacy and toxicity of two doses of trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus. Dutch AIDS Treatment Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9862944" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10395851" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2008181" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : A controlled study of inhaled pentamidine for primary prevention of Pneumocystis carinii pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1507374" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Hospital outbreak of multidrug-resistant Mycobacterium tuberculosis infections. Factors in transmission to staff and HIV-infected patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1616211" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : An outbreak of tuberculosis caused by multiple-drug-resistant tubercle bacilli among patients with HIV infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7555166" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : AIDS-related spontaneous pneumothorax. Risk factors and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9241108" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9806044" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Risk factors for primary Pneumocystis carinii pneumonia in human immunodeficiency virus-infected adolescents and adults in the United States: reassessment of indications for chemoprophylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10218526" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10219064" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11692302" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Discontinuation of Pneumocystis carinii prophylaxis in patients infected with human immunodeficiency virus: a meta-analysis and decision analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17690568" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Pneumocystis jiroveci pneumonia prophylaxis is not required with a CD4+ T-cell count&lt;200 cells/microl when viral replication is suppressed.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32448894" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Withholding Primary Pneumocystis Pneumonia Prophylaxis in Virologically Suppressed Patients With Human Immunodeficiency Virus: An Emulation of a Pragmatic Trial in COHERE.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11574913" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Trimethoprim-sulfamethoxazole (TMP-SMZ) dose escalation versus direct rechallenge for Pneumocystis Carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with previous adverse reaction to TMP-SMZ.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8442919" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Efficacy and safety of rechallenge with low-dose trimethoprim-sulphamethoxazole in previously hypersensitive HIV-infected patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11015150" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Reduced toxicity with gradual initiation of trimethoprim-sulfamethoxazole as primary prophylaxis for Pneumocystis carinii pneumonia: AIDS Clinical Trials Group 268.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
